Tuesday, March 18, 2025 | 02:31 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Despite price control measures, multinational medical firms fare well

Indian companies importing their devices from abroad still remains only around 20 per cent of the total imports

Novartis
Premium

Novartis is addressing the pricing question with a new type of agreement: For patients whose care is covered by the US govt programmes, the company will only get paid if patients show signs that the treatment is working within a month | Photo: istock

Veena Mani
Despite price control measures on medical devices, multinational firms seem to have done well. They not only secured almost 80 per cent of the total 2,000 import licenses granted in the last one year but also managed to gain market share in key segments like stents. 

Sources in the Central Drug Standards Control Organisation (CDSCO) said that MNC firms have secured around 80 per cent of the device import licenses granted in the past year. These include names like Johnson and Johnson, Abbott, Medtronic, Boston Scientific and Becton Dickinson, among others. Some of these companies are importing knee implants and

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in